The benefits of mass spectrometry for expediting biologics to patients
European Pharmaceutical Review
SEPTEMBER 20, 2023
Approaching characterisation of complex molecules from both a drug product and drug substance perspective in a holistic manner, with previous technical experience combined with cutting edge technologies, can enable delivery of successful CMC outcomes. Ian has previously worked for Allergan, AbbVie and Pharmaron gene therapy.
Let's personalize your content